Clinical Trial Update: Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating Sacituzumab tirumotecan for neoadjuvant therapy in early-stage triple-negative breast cancer; the study is not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Xijing Hospital | Conditions: Triple -Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING